SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular ...

Lenvima plus Keytruda with TACE significantly improved progression-free survival in unresectable, non-metastatic hepatocellular carcinoma compared to TACE with placebo. The study reported a median ...

A meta-analysis found that patients with early and intermediate-stage hepatocellular carcinoma who received external beam radiation therapy (EBRT) demonstrated better local control and ...

The efficacy of transarterial techniques can be assessed in terms of imaging response (CT scan), biologic response (AFP), degree of tumor necrosis, patient survival or quality of life. The most ...

Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...

Mortality and 30-day readmissions among hepatocellular carcinoma patients hospitalized for portal vein thrombosis: A nationwide analysis. This is an ASCO Meeting Abstract from the 2026 ASCO ...

Tick marks indicate censoring of data. No participants had an albumin-bilirubin grade of 3, so this group has not been included in subgroup definitions here. BCLC=Barcelona Clinic Liver Cancer.

National Quality Improvement Initiative to Increase Smoking Cessation Assistance in Commission on Cancer Programs and National Accreditation Program for Breast Centers Patients with unresectable HCC ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally. Often diagnosed at advanced stages, the therapeutic ...